Introduction
Interleukin (IL)-11 is a stromal cell-derived pleiotropic growth factor that exerts multiple effects on hematopoietic and nonhematopoietic systems. 1, 2 In the hematopoietic system, IL-11 promotes the growth and maturation of megakaryocyte progenitor cells (colony-forming unit-megakaryocyte (CFU-MK) and burst-forming unit-megakaryocyte (BFU-MK)) in the presence of IL-3. [3] [4] [5] Recently, these megakaryocytes were reported to express the IL-11 receptor ␣ chain (IL-11R␣) 5 and we reported that signaling through gp130 activated by IL-6 and soluble IL-6R complex induced megakaryocyte maturation in It was reported that administration of IL-11 to mice pretreated with chemotherapy significantly accelerated the multilineage recovery of hematopoiesis. 10, 11 Moreover, recent clinical trials of recombinant human (rh) IL-11 in cancer patients receiving chemotherapy have demonstrated it has the potential to reduce chemotherapy-induced severe thrombocytopenia. 12, 13 However, use of rhIL-11 in patients with hematological malignancies may be restricted because of its stimulatory effect on myeloid leukemic cells. [14] [15] [16] Therefore, it seems important to re-evaluate the effect of rhIL-11 on growth of leukemic progenitor cells (L-CFU) in the presence of various cytokines, including IL-3, granulocyte-macrophage colonystimulating factor (GM-CSF), granulocyte (G)-CSF, SCF, Flt3 ligand (FL), and TPO.
In the present study, we investigated the effect of IL-11 on the growth of L-CFU from patients with various types of AML in the presence or absence of the above-mentioned cytokines. The expression of IL-11R␣ and gp130, its signal transducing ␤ receptor, 17 by myeloid leukemic cells was also examined using flow cytometry. Our data clearly demonstrated that myeloid leukemic cells expressing high levels of IL-11 R␣ and gp130 proliferated in response to IL-11 in the presence of additional cytokines. These findings suggest that it may be possible to predict the response of L-CFU to exogenous IL-11 in vivo by a simple receptor assay using standard flow cytometry.
Materials and methods

Patients
Thirty-three patients with AML were studied. Their clinical and laboratory characteristics are presented in Table 1 . The diagnosis of AML was established by standard morphological and cytochemical criteria according to the French-AmericanBritish (FAB) classification. 18 All samples of bone marrow (BM) or peripheral blood (PB) contained more than 50% leukemic blast cells and were collected before induction chemotherapy. All patients were treated with chemotherapy as recommended by the Japan Acute Leukemia Study Group (JALSG). 19 Cytogenetic analysis of leukemic cells was performed using Gbanding as described elsewhere. 20 
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Preparation of leukemic cells
BM or PB samples were diluted with Ca 2+ -and Mg 2+ -free phosphate-buffered saline (PBS − ), layered over Ficoll-Paque (Pharmacia Biotech, Uppsala, Sweden), and centrifuged for 30 min at 400 g. Interface cells were collected, washed, cryopreserved as reported elsewhere, 21, 22 and stored frozen before use. For the present study, cells were thawed as reported elsewhere 22 and resuspended in ␣-medium containing 10% fetal calf serum (FCS, Flow Laboratories, McLean, VA, USA). Nonadherent (NA) cells were recovered after 1 h of incubation in plastic dishes. The viability of thawed leukemic blast cells assessed by trypan blue dye exclusion was always greater than 90%. In most samples, the NA cells contained more than 90% leukemic blast cells (data not shown). These cells were used for clonal leukemic cell culture and flow cytometric analysis of the expression of IL-11R␣ and gp130.
Recombinant growth factors
Purified bacterially derived rh IL-3, GM-CSF, G-CSF, and SCF were generously supplied by Kirin Brewery (Tokyo, Japan). Purified rh TPO was prepared by the TPO Production Group (Kirin Brewery) and was provided by Dr Hiroshi Miyazaki (Kirin Brewery). Purified bacterially derived rhIL-11 was a kind gift from Yamanouchi Pharmaceutical (Tokyo, Japan) and had a specific activity of 1.39 × 10 6 U/mg. A soluble form of rhflt3 ligand (FL) produced in yeast was kindly provided by Dr Stewart D Lyman (Immunex, Seattle, WA, USA). 23 
Cell lines
The T-10 cell line (kindly supplied by Yamanouchi Pharmaceutical), an IL-11-dependent murine plasmacytoma line 24 was used to determine the optimum concentration of anti-IL-11R antibody for flow cytometry, as described later. K-562 25 and HL-60 26 cells were also used as positive controls for IL-11R␣ and gp130 expression.
Clonogenic assay for leukemic colony-forming units (L-CFU)
Semisolid cultures of AML blast cells isolated from BM or PB were performed in 35-mm Petri dishes (No. 171099; Nunc, Naperville, IL, USA), using the reported method with some modifications. [14] [15] [16] 27, 28 One milliliter of culture medium contained 5 × 10 4 to 1 × 10 5 leukemic blast cells, a 1.2% concentration of 1500 centipoise methylcellulose (Shinetsu Chemical, Tokyo, Japan), 30% FCS (Flow Laboratories), 1% deionized fraction V bovine serum albumin (BSA) (Sigma Chemical Co, St Louis, MO, USA), 5 × 10 −5 mol/l 2-mercaptoethanol (ME) (Sigma), and one or more recombinant human CSFs. Dishes were incubated at 37°C in a fully humidified atmosphere flushed with 5% CO 2 . On days 10 to 14 of incubation, all leukemic colonies containing 20 or more cells were counted under an inverted microscope and the plating efficiency (PE) was calculated (PE 1 ). A time course study of leukemic colony formation revealed that the number of colonies reached a plateau on days 10 to 14 in our culture system (data not shown).
The final concentrations of each CSF used were as follows: IL-3, 10 ng/ml; GM-CSF, 10 ng/ml; G-CSF, 20 ng/ml; SCF, 20 ng/ml; TPO, 100 ng/ml; FL, 100 ng/ml; IL-11, 100 U/ml (72 ng/ml). These concentrations supported plateau levels of leukemic colony formation in preliminary titration experiments (data not shown).
In some cases, L-CFU-derived colonies were picked up individually with a fine Pasteur pipette, spread on glass slides, and stained with May-Grü nwald-Giemsa (M-G) for morphological analysis. Most colonies consisted of immature leukemic blast cells (data not shown).
Replating of primary leukemic cell colonies
Primary leukemic cell colonies were picked up on day 10 of incubation by Eppendorf micropipette and were replated in methylcellulose as reported 29, 30 with some modifications. Briefly, pooled leukemic blast cells were washed twice with ␣-medium and then replated at a concentration of 1 × 10 4 cells in 1 ml of culture medium containing the same ingredients as described for primary leukemic colony formation. A part of the pooled cells was used for morphological examination after M-G staining. Colonies containing more than 20 cells were scored on days 10 to 14 of incubation, and their plating efficiency was calculated (PE 2 ).
Immunofluorescence study
Cell surface expression of human IL-11R␣ and gp130 was investigated by flow cytometry, as reported elsewhere. 6, 21, 31, 32 Leukemic cells containing more than 90% blasts were pelleted before staining with the following antibodies: polyclonal antibody (Ab) to human/mouse IL-11R␣ chain (N-20, rabbit IgG; Santa Cruz Biotechnology, Santa Cruz, CA, USA) 5 and purified anti-human gp130 monoclonal Ab (AM64, mouse IgG 1 , kindly provided by Dr Kiyoshi Yasukawa (Tosoh, Kanagawa, Japan)). 33 Purified anti-human gp130, and IL-11R␣ chain Abs were biotinylated as described elsewhere. 6 For detection of IL-11R and gp130, incubation was respectively performed with these biotinylated Abs (2 g or 5 g per 10 6 cells) for 30 min at room temperature. Concentrations of anti-IL-11R␣ Ab greater than 2 g/10 6 cells showed a plateau fluorescence intensity in preliminary titration experiments using T-10 cells (data not shown). After washing with PBS − containing 2% FCS (staining medium), cells were incubated with streptavidin-phycoerythrin (PE) (Becton Dickinson Immunocytometry Systems, San Jose, CA, USA) for 30 min on ice. Subsequently, all cells were washed twice with the staining medium and were kept on ice for flow cytometry or single cell sorting. Negative controls included unstained cells and cells only stained with PE-conjugated isotype control IgG or only stained with streptavidin-PE.
Flow cytometric analysis was performed with a FACS Calibur or FACS Vantage (Becton Dickinson), as reported elsewhere.
6,21,31,32 First, a gate was established for intermediate forward scatter (FSC) and low side scatter (SSC), defined as the blast cell window. A histogram displaying PE fluorescence (IL-11R␣ or gp130) was then generated from the gated events. We evaluated the pattern of IL-11R␣ and gp130 expression on leukemic cells by the percent expression and the fluorescence intensity (FI). FI was a relative value that was calculated as the peak channel number of each sample divided by the peak channel number of the control.
Clone sorting and single cell culture
Clone sorting was performed with a FACS Vantage (Becton Dickinson) using an Automated Cell Deposition Unit (CloneCyt), as reported previously. 6, 21 Sorting gates were established in the blast cell window as described above. All three AML M5 samples used in these experiments strongly expressed IL-11R␣. Serum-free liquid suspension culture was performed in 96-well plates. Single cells were incubated in wells containing 100 l of ASF 104 medium 34 supplemented with 1% BSA, 5 × 10 −5 mol/l 2-ME, and the designated factors. Incubation was done for up to 28 days at 37°C in a fully humidified atmosphere flushed with a combination of 5% CO 2 , 5% O 2 , and 90% N 2 . On days 4, 7, 10, 14, 21 and 28, each well was scanned under an inverted microscope. Fifty microliters of the above-mentioned fresh medium was carefully added to each well on days 7, 14 and 21. When a positive well was identified, the number of cells per clone was directly counted in situ.
Statistical analysis
Statistical significance was determined using the two-tailed Student's t-test and the Mann-Whitney rank-sum test.
Results
Clonal proliferation of leukemic progenitor cells in the presence of single CSFs
As seen in Figure 1 and Table 2a , 24 out of 33 (72.7%) patients with AML showed leukemic cell colony formation in the presence of various CSFs, and five of them (one M3 and four M5) showed spontaneous colony formation. Of note was that all M4 and M5 patients showed leukemic colony formation. On the other hand, only 50 to 70% of the M0 to M3 patients showed leukemic colony formation. The number of leukemic colonies stimulated by single CSFs (including IL-3, GM-CSF, G-CSF, SCF, TPO, and FL) was 1 to 800 per 1 × 10 5 seeded cells (Figure 1) . Therefore, the plating efficiency (PE 1 ) showed a wide range from 0.001%ෂ0.8%. When over 10 leukemic colonies per 1 × 10 5 seeded cells were found, colony formation was evaluated as significant. IL-11 alone did not support leukemic colony formation, except in one M3 patient showing spontaneous colony formation. In the presence of IL-3, GM-CSF, or G-CSF, there was significant leukemic colony formation by approximately 40 to 50% of the AML patients who did not show spontaneous colony formation ( Figure 1 , Table 2b ). In contrast, the incidence of leukemic colony formation supported by SCF, TPO, or FL was under 25%. In the presence of TPO alone, only one out of 25 patients tested showed leukemic colony formation. Addition of IL-11 to cultures containing any one of the above-mentioned CSFs did not 5 cells, colony formation was evaluated as significant. IL-11 alone did not support significant colony formation, except in one M3 patients (case 16) who showed spontaneous colony formation. Approximately 40 to 50% of AML patients showed significant leukemic colony formation in the presence of IL-3, GM-CSF, or G-CSF. In contrast, less than 25% of patients showed leukemic colony formation in the presence of SCF, TPO, and FL. Addition of IL-11 to cultures containing any of the above-mentioned cytokines did not significantly change the incidence of leukemic colony formation. Patients, in whom the number of leukemic colony significantly increased by the addition of IL-11, are designated by solid lines.
significantly change the incidence of leukemic colony formation (ie 24/33 to 23/33) (Table 2a) . PE 1 was reported to reflect terminal division or perhaps a process analogous to differentiation of L-CFU. 29, 30, 35 Therefore, IL-11 alone could not induce terminal differentiation or loss of the proliferative potential of L-CFU.
Enhancement of primary leukemic colony formation by IL-11
Next, we examined the effect of IL-11 on primary leukemic colony formation by L-CFU in the presence of various cytokines. As shown in Table 3a , the number of leukemic colonies significantly increased by the addition of IL-11 in 16 out of 33 patients. Particularly in seven out of nine M5 patients, IL-11 enhanced leukemic colony formation supported by various CSFs. Interestingly, IL-11 acted synergistically with G-CSF or IL-3 in 12 (75%) or eight (50%) of these 16 patients, respectively (Table 3b) . Fold increase of the number of leukemic colony ranged from 1.2 to 5.0 with the mean fold increase being 2.1 ± 0.9. Patients who showed the increment of leukemic colony formation by the addition of IL-11 are designated in Figure 1 . These results indicated that IL-11 enhanced PE 1 in the presence of other cytokines. In other words, IL-11 enhanced the terminal division or differentiation of L-CFU particularly in the presence of G-CSF. Recently, G-CSF has been widely used clinically for the treatment of myelosuppression induced by chemotherapy in AML patients. Therefore, such an effect might be clinically desirable even if the number of leukemic cells increased transiently.
Effect of IL-11 on secondary leukemic colony formation by L-CFU
The effect of IL-11 on secondary leukemic colony formation (PE 2 ) supported by G-CSF was examined in three M5 patients who showed PE 1 enhancement by IL-11. Their cells showed strong expression of IL-11R␣ and gp130, as described later. The results are presented in Table 4 . The PE 2 values for colonies developing in the presence of G-CSF+IL-11 were significantly lower than those obtained in the presence of G-CSF alone. Particularly, PE 2 decreased from 4.26% to 0.57% in case 27 (M5b). These data indicated that IL-11 reduced the PE 2 of L-CFU supported by G-CSF. Morphological analysis of cells derived from pooled primary colonies revealed that the percentage of leukemic blast cells was decreased after culture with G-CSF+IL-11, accompanying the increase of differentiated monocytic cells and macrophages. Further studies showed that PE 2 increased markedly in the presence of G-CSF alone compared with PE 1 , except in case 32, and that this elevation of PE 2 was suppressed by IL-11. These results suggested that G-CSF stimulated the terminal division as well as the self-renewal potential of L-CFU. In contrast, IL-11 initially enhanced the terminal division of L-CFU supported by G-CSF, but continued stimulation with IL-11 subsequently suppressed the self-renewal of L-CFU.
Proliferation of clone-sorted single leukemic cells in serum-free liquid suspension culture
The synergistic effect of IL-11 on the proliferation of L-CFU supported by G-CSF was serially investigated for 4 weeks using single cell serum-free liquid suspension culture. We performed three independent experiments using three different AML M5 samples which strongly expressed IL-11R␣. The pattern of proliferation of single leukemic cells of one representative M5 case is presented in Figure 2 . In the presence of IL-11 alone, only a few clones divided once or twice, but disappeared by day 28 of incubation. As described above, G-CSF alone stimulated a certain number of single leukemic cells, while the combination of G-CSF and IL-11 synergistically induced single cell proliferation, suggesting that IL-11 enhanced the G-CSF-supported clonogenic growth of leukemic blast cells. The total number of clones proliferating significantly increased in the presence of G-CSF+IL-11 compared with that in the presence of G-CSF alone. However, total number of clones containing more than eight cells produced over the 28 days of culture was almost comparable in both culture conditions. In addition, large clones containing over 20 cells completely disappeared by day 28 of incubation in the presence of G-CSF+IL-11. In contrast, in the presence of G-CSF alone, half of the surviving clones still contained over 20 cells on day 28. These results suggested that the proliferation of quiescent leukemic progenitor cells was stimulated by the ) derived from primary leukemic colonies, which were harvested and pooled on day 10 of incubation, were replated in secondary cultures containing the same medium ingredients as those used for primary cultures. PE 2 , plating efficiency in secondary culture. c A portion of the pooled cells was morphologically examined using cytocentrifuged preparations stained by May-Grü nwald-Giemsa to determine the percentage of blast cells. d Case No. 32 (M5) showed spontaneous colony formation. *P Ͻ 0.02, **P Ͻ 0.01, ***P Ͻ 0.001. addition of IL-11, and that IL-11 acted primarily to enhance the speed of proliferation and differentiation of L-CFU.
In the presence of G-CSF+IL-11, a significantly larger number of single leukemic blast cells survived over 2 weeks of culture without cell division compared with that in the presence of G-CSF alone. These results suggested that IL-11 might function as a survival factor for L-CFU.
Expression of IL-11R␣ and gp130 by leukemic cells
Finally, the expression of IL-11R␣ and gp130 by leukemic cells was examined using flow cytometry in 22 out of 33 patients to determine if their leukemic cells were direct targets for IL-11. As shown in Table 5 , gp130 was ubiquitously expressed by all types of AML cells, but M5 cells most strongly expressed this receptor. On the other hand, the expression of IL-11R␣ was quite heterogeneous, with the mean percent expression being high (approximately 80 to 90%) in M1, M3, and M5 patients. Among them, the mean fluorescence intensity (FI) was significantly higher in M5 patients than in other types of AML. One M5 patient had cells with weak IL-11R␣ expression that showed spontaneous colony growth, while two M0 patients had cells showing very weak IL-11R␣ expression. Control HL-60 and K-562 cells, both IL-11-responsive cell lines, 25, 26 showed strong expression of both IL-11R␣ and gp130.
Correlation of IL-11R␣ and gp130 expression with the responsiveness of leukemic cells to IL-11
To assess the biological significance of the expression of gp130 and IL-11R␣ by leukemic cells, the effect of IL-11 on L-CFU was examined in the presence of various CSFs. The results are presented in Figure 3 . In group A, L-CFU growth was significantly enhanced by IL-11. On the other hand, L-CFU did not respond to IL-11 in group B. Group A consisted of one M1, one M2, three M3, one M4, and five M5 patients. Group B consisted of two M0, six M2, one M3, one M5, and one M6 patients. The M5 patient in this group showed spontaneous colony growth.
Expression of gp130 was almost ubiquitous in both groups, but the fluorescence intensity (FI) was significantly higher in group A than in group B (P Ͻ 0.0009, Mann-Whitney ranksum test). There was a striking difference in the expression of IL-11R␣, with the mean expression percent being 88.5 ± 11.8% in group A and 50.4 ± 21.1% in group B (P Ͻ 0.0002, Mann-Whitney rank-sum test). Moreover, the mean Relative value (peak channel of each sample/peak channel of control).
Figure 3
Percent expression and relative fluorescence intensity (FI) of gp130 and IL-11R␣. In group A, L-CFU growth was significantly enhanced by IL-11. This group consisted of one M1, one M2, three M3, one M4, and five M5 patients. Group B was patients whose L-CFU growth was not enhanced by IL-11. This group consisted of two M0, six M2, one M3, one M5, and one M6 patients. gp130 was ubiquitously expressed by AML cells from both groups, but the FI was significantly larger in group A than in group B (P Ͻ 0.0009, MannWhitney rank-sum test). In contrast, the expression of IL-11R␣ was quite heterogeneous. Both the percent expression (P Ͻ 0.0002) and the FI (P Ͻ 0.0018) of IL-11R␣ were significantly greater in group A than in group B. FI was a relative value calculated as the peak channel number of each sample divided by the peak channel number of the control.
FI was 54.0 ± 57.6 in group A vs 10.9 ± 14.6 in group B (P Ͻ 0.0018, Mann-Whitney rank-sum test). These results clearly indicated that AML cells (chiefly M5) with high levels of IL-11R␣ chain and gp130 expression showed a proliferative response to IL-11 in the presence of other CSFs.
Discussion
We investigated the colony-forming capacity of leukemic progenitor cells in 33 patients with AML using various CSFs as stimulators. According to the FAB classification, M4 and M5 patients showed a higher incidence of colony formation (2/2 for M4 and 9/9 for M5) than M0 to M3 patients (1/2 for M0, 2/3 for M1, 5/9 for M2, and 5/7 for M3). In our experiments, five patients (one M3 and four M5) showed spontaneous colony formation. All five patients had over 90% leukemic blast cells, suggesting the presence of autocrine growth mechanisms as reported previously. 36 It is well documented that the in vitro growth of myeloid leukemic progenitor cells is dependent on various CSFs, including IL-3, GM-CSF, G-CSF, SCF, TPO, and FL. [14] [15] [16] [36] [37] [38] In fact, approximately 70 to 80% of the AML patients tested in this study had leukemic cells that showed colony formation (including spontaneous colony formation) in the presence of one or more of the above-mentioned CSFs. Among them, IL-3, GM-CSF, and G-CSF were equally effective at stimulating the growth of L-CFU, while SCF, TPO, and FL had a much weaker effect on L-CFU growth.
In this study, we attempted to precisely define the influence of IL-11 on L-CFU in order to confirm its safety for use in treating thrombocytopenia induced by chemotherapy in AML patients. We found that IL-11 alone did not support leukemic colony formation, except in one M3 patient whose cells showed spontaneous colony formation. In our experiments, we used an IL-11 concentration of 100 U/ml (72 ng/ml) in cultures. As reported previously, 39 the mean plasma C max value was under 20 ng/ml after subcutaneous administration of IL-11 at doses of 3 to 50 g/kg. Therefore, use of IL-11 alone in AML patients may not have a significant effect on leukemic progenitor cells. However, in the presence of other CSFs, especially 20 ng/ml of G-CSF, IL-11 markedly enhanced leukemic colony growth in vitro, particularly the growth of M5 AML cells. Our clone sorting experiments clearly indicated that this was a direct effect of IL-11 and that it could be detected at the single leukemic progenitor cell level at least in M5 AML patients. The normal serum level of G-CSF was reported to be under 30 pg/ml. 40 After subcutaneous administration of G-CSF at a dose of 2 g/kg for 14 days, the serum level reached 10 ng/ml. 41 In addition, several cytokines including G-CSF, show increased serum levels (so-called hypercytokinemia) after stem cell transplantation procedures, such as bone marrow transplantation (BMT) and peripheral blood stem cell transplantation (PBSCT). 42, 43 Therefore, it seems likely that the administration of IL-11 to accelerate platelet recovery in these clinical settings affects the terminal division or differentiation of L-CFU.
In order to further clarify the effect of IL-11 on L-CFU, the expression of IL-11R␣ and gp130 (its signal transducing ␤ receptor) by leukemic blast cells was examined. We found that gp130 was ubiquitously expressed by all types (M0 to M6) of AML, as reported previously. 44 In contrast, expression of IL-11R␣ showed wide variation, but 80 to 90% of M1, M3, and M5 cells expressed this receptor and the intensity of expression was significantly higher on M5 cells. In seven out of nine M5 patients, growth of L-CFU was enhanced by the addition of IL-11 in the presence of other CSFs. From the point of signal transduction, this growth enhancement was consistent with receptor expression pattern, ie there was a clear relationship between the level of IL-11R␣ expression and the ligand indicating the presence of the functional receptor. An important finding was that the in vitro growth response of leukemic progenitor cells to IL-11 may be predicted from the level of expression of IL-11R␣ and gp130. Our data are consistent with an earlier report 44 that semiquantitation of IL-6R and gp130 mRNA expression by the reverse transcriptasepolymerase chain reaction method is useful for predicting the responsiveness of leukemic cells to IL-6.
The prognosis of AML has been greatly improved by intensive combination chemotherapy 19, 45, 46 and by the establishment of BMT. 47 However, M5 AML still has a less favorable outcome compared with other types of AML, including M3, M4, and M2. 46 It is well documented that a high proportion of L-CFU are in the S-phase of the cell cycle, and thus are relatively sensitive to chemotherapy, 14, 37, 48 while dormant or long G 0 /G 1 leukemic progenitor cells play an important role in the relapse of leukemia because of resistance to chemotherapy. 37, 48 Our single cell culture studies of M5 leukemic blast cells suggested that a combination of IL-11 and G-CSF may recruit quiescent leukemic progenitor cells into the cell cycle. These results provide a rationale for a possible novel treatment protocol, in which coadministration of IL-11 and G-CSF would be used to induce proliferation of dormant leukemic progenitor cells, especially in M5 patients, resulting in augmentation of the effectiveness of cell cycle-specific anticancer drugs. This new method will be applied to therapy for refractory M5 patients in the future.
Moreover, replating experiments clearly showed that IL-11 significantly suppressed PE 2 of L-CFU in the presence of G-CSF, and that this effect may be caused by the induction of L-CFU differentiation. PE 2 is reported to reflect the self-renewal potential of L-CFU and is not only correlated with the success of remission induction, but also with the survival time of AML patients. 29, 35, 49 Therefore, suppression of PE 2 by IL-11 is clinically desirable. Recently, we reported that signaling through gp130 activated by IL-6/soluble IL-6R complex may mainly contribute to the maturation of hematopoietic progenitor cells in the presence of SCF and IL-3. 6 The present study yielded findings consistent with our previous results and suggested that signaling through gp130 could act as a maturational stimulus for malignant hematopoiesis and antagonize the selfrenewal potential of L-CFU.
In conclusion, IL-11 alone is probably a safe treatment for thrombocytopenia caused by chemotherapy in AML patients. Since IL-11 affected the proliferation of L-CFU (PE 1 ) in the presence of G-CSF, careful attention should be taken when IL-11 plus G-CSF is administered, especially in AML M5 patients. Our receptor analysis revealed that the IL-11 responder group expressed significantly stronger level of IL-11R␣ than the IL-11 non-responder group. These results suggest that the fluorescent intensity (FI) of IL-11R␣ may predict the responsibility of L-CFU to IL-11, only if a patient has a strong FI (over 50) or a weak FI (under 5.0). Therefore, this simple receptor assay may provide useful information for safe treatment with IL-11 in various types of AML.
